# Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

> **NCT02842541** · PHASE1 · WITHDRAWN · sponsor: **Eleven Biotherapeutics**

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** EBI-031

## Key facts

- **NCT ID:** NCT02842541
- **Lead sponsor:** Eleven Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2017-10
- **Final completion:** 2018-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** New study planned.
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842541, "Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02842541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*